Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Line 19: | Line 19: | ||
=Section Editors= | =Section Editors= | ||
{| border="1" style="text-align:center; width:100%;" | {| border="1" style="text-align:center; width:100%;" | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Dermatologic Oncology''' |
|- | |- | ||
− | |rowspan=4|[[File:Bethbuchbinder.jpg|thumb|upright=0.4|center]] | + | |rowspan=4 style="background-color:#F0F0F0"|[[File:Bethbuchbinder.jpg|thumb|upright=0.4|center]] |
|rowspan=4|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn] | |rowspan=4|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn] | ||
− | |[[Melanoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Melanoma]] |
|- | |- | ||
− | |[[Merkel cell carcinoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Merkel cell carcinoma]] |
|- | |- | ||
− | |[[Basal cell and squamous cell skin cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Basal cell and squamous cell skin cancer]] |
|- | |- | ||
− | |[[Cutaneous T-cell lymphoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Cutaneous T-cell lymphoma]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology''' |
|- | |- | ||
− | |rowspan=5|Coming soon | + | |rowspan=8 style="background-color:#F0F0F0"|Coming soon |
+ | |rowspan=8|<big>Neeta Venepalli, MD<br>Chicago, IL</big> | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Anal cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Colon cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Gastric cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Hepatobiliary cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]] | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#deebf7"|[[Rectal cancer]] | ||
+ | |- | ||
+ | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology''' | ||
+ | |- | ||
+ | |rowspan=5 style="background-color:#F0F0F0"|Coming soon | ||
|rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn] | |rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn] | ||
− | |[[Bladder cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Bladder cancer]] |
|- | |- | ||
− | |[[Penile cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Penile cancer]] |
|- | |- | ||
− | |[[Prostate cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Prostate cancer]] |
|- | |- | ||
− | |[[Renal cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Renal cancer]] |
|- | |- | ||
− | |[[Testicular cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Testicular cancer]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gynecologic Oncology''' |
|- | |- | ||
− | |rowspan=4|[[File:BrandonSeagle.jpg|thumb|upright=0.4|center]] | + | |rowspan=4 style="background-color:#F0F0F0"|[[File:BrandonSeagle.jpg|thumb|upright=0.4|center]] |
|rowspan=4|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big> | |rowspan=4|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big> | ||
− | |[[Cervical cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Cervical cancer]] |
|- | |- | ||
− | |[[Germ cell tumors]] | + | |style="width: 25%; background-color:#deebf7"|[[Germ cell tumors]] |
|- | |- | ||
− | |[[Ovarian cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Ovarian cancer]] |
|- | |- | ||
− | |[[Uterine cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Uterine cancer]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Neuro-Oncology''' |
|- | |- | ||
− | |rowspan=4|[[File:SeemaNagpal.jpg|thumb|upright=0.4|center]] | + | |rowspan=4 style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|thumb|upright=0.4|center]] |
|rowspan=4|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big> | |rowspan=4|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big> | ||
− | |[[Central nervous system (CNS) cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Central nervous system (CNS) cancer]] |
|- | |- | ||
− | |[[CNS leukemia]] | + | |style="background-color:#fee0d2"|[[CNS leukemia]] |
|- | |- | ||
− | |[[CNS lymphoma]] | + | |style="background-color:#fee0d2"|[[CNS lymphoma]] |
|- | |- | ||
− | |[[Glioblastoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Glioblastoma]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma''' |
|- | |- | ||
− | |rowspan=4|Coming soon | + | |rowspan=4 style="background-color:#F0F0F0"|Coming soon |
|rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | |rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | ||
− | |[[Ewing's sarcoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Ewing's sarcoma]] |
|- | |- | ||
− | |[[Gastrointestinal stromal tumor]] | + | |style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor]] |
|- | |- | ||
− | |[[Osteosarcoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Osteosarcoma]] |
|- | |- | ||
− | |[[Sarcoma|Sarcoma (other types)]] | + | |style="width: 25%; background-color:#deebf7"|[[Sarcoma|Sarcoma (other types)]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Thoracic Oncology''' |
|- | |- | ||
− | |rowspan=5|[[File:TravisOsterman.jpg|thumb|upright=0.4|center]] | + | |rowspan=5 style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|thumb|upright=0.4|center]] |
|rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | |rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | ||
− | |[[Esophageal cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]] |
|- | |- | ||
− | |[[Mesothelioma]] | + | |style="width: 25%; background-color:#deebf7"|[[Mesothelioma]] |
|- | |- | ||
− | |[[Non-small cell lung cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Non-small cell lung cancer]] |
|- | |- | ||
− | |[[Small cell lung cancer]] | + | |style="width: 25%; background-color:#deebf7"|[[Small cell lung cancer]] |
|- | |- | ||
− | |[[Thymoma]] | + | |style="width: 25%; background-color:#deebf7"|[[Thymoma]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms''' |
|- | |- | ||
− | |rowspan=7|Coming soon | + | |rowspan=7 style="background-color:#F0F0F0"|Coming soon |
|rowspan=7|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> | |rowspan=7|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> | ||
− | |[[Chronic myelogenous leukemia]] | + | |style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]] |
|- | |- | ||
− | |[[Chronic myelomonocytic leukemia]] | + | |style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia]] |
|- | |- | ||
− | |[[Essential thrombocythemia]] | + | |style="background-color:#fee0d2"|[[Essential thrombocythemia]] |
|- | |- | ||
− | |[[Hypereosinophilic syndrome]] | + | |style="background-color:#fee0d2"|[[Hypereosinophilic syndrome]] |
|- | |- | ||
− | |[[Myelofibrosis]] | + | |style="background-color:#fee0d2"|[[Myelofibrosis]] |
|- | |- | ||
− | |[[Polycythemia vera]] | + | |style="background-color:#fee0d2"|[[Polycythemia vera]] |
|- | |- | ||
− | |[[Systemic mastocytosis]] | + | |style="background-color:#fee0d2"|[[Systemic mastocytosis]] |
|- | |- | ||
− | !colspan="3" align="center" style="color:white; font-size:125%; background-color:# | + | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Plasma Cell Dyscrasias''' |
|- | |- | ||
− | |rowspan=3|[[File:Headshot Cowan.jpg|thumb|upright=0.4|center]] | + | |rowspan=3 style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|thumb|upright=0.4|center]] |
|rowspan=3|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn] | |rowspan=3|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn] | ||
− | |[[Multiple myeloma]] | + | |style="background-color:#fee0d2"|[[Multiple myeloma]] |
|- | |- | ||
− | |[[Light-chain (AL) amyloidosis]] | + | |style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]] |
|- | |- | ||
− | |[[Plasma cell leukemia]] | + | |style="background-color:#fee0d2"|[[Plasma cell leukemia]] |
|- | |- | ||
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#756bb1"|'''Transplant''' | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#756bb1"|'''Transplant''' | ||
|- | |- | ||
− | |rowspan=4|[[File:Arichall_400x400.jpg|thumb|upright=0.4|center]] | + | |rowspan=4 style="background-color:#F0F0F0"|[[File:Arichall_400x400.jpg|thumb|upright=0.4|center]] |
|rowspan=4|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1] | |rowspan=4|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1] | ||
− | |[[Stem cell mobilization]] | + | |style="background-color:#efedf5"|[[Stem cell mobilization]] |
|- | |- | ||
− | |[[Allogeneic HSCT conditioning regimens]] | + | |style="background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]] |
|- | |- | ||
− | |[[Autologous HSCT conditioning regimens]] | + | |style="background-color:#efedf5"|[[Autologous HSCT conditioning regimens]] |
|- | |- | ||
− | |[[Graft versus host disease (GVHD)]] | + | |style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] |
|- | |- | ||
|} | |} |
Revision as of 15:27, 4 October 2017
Please feel free to contact us with any questions or inquiries, at the email addresses below.
Editor-in-Chief
Peter C. Yang, MD Boston, MA [email protected] Twitter: Hem_Onc |
Deputy Editor
Jeremy L. Warner, MD, MS Nashville, TN [email protected] Twitter: Hemoncwarner |